N-乙酰基-L-异谷氨酰胺 | 25460-87-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 谷氨酰胺类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-乙酰基-L-异谷氨酰胺
• 英文名称: (S)-4-Acetamido-5-amino-5-oxopentanoic acid
• 英文别名: (4S)-4-acetamido-5-amino-5-oxopentanoic acid
• CAS: 25460-87-1
• 化学式: C₇H₁₂N₂O₄
• 分子量: 188.183
• InChiKey: ZAFUMUJQGCBVPX-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  2-diazo-2-(3-methoxyphenyl)-1-(pyrrolidin-1-yl)ethan-1-one 、 N-乙酰基-L-异谷氨酰胺 以 乙腈 为溶剂， 22.0 ℃ 、101.33 kPa 条件下， 反应 19.0h， 生成
  参考文献：
  名称：

  Two-Step Synthesis of α-Aryl-α-diazoamides as Modular Bioreversible Labels

  摘要：

  DOI：

  10.1021/acs.orglett.1c00793
• 作为产物：
  描述：

  L-异谷氨酰胺 、 4-硝基苯基乙酸酯 生成 N-乙酰基-L-异谷氨酰胺
  参考文献：
  名称：

  Fauchere, Jean-Luc; Pliska, Vladimir, European Journal of Medicinal Chemistry, 1983, vol. 18, # 4, p. 369 - 376

  摘要：

  DOI：

文献信息

• TRICYCLIC COMPOUNDS BEARING ACYLOXYMETHOXYCARBONYL PENDANTS
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1219606A1

  公开（公告）日：2002-07-03

  There are provided a compound represented by the formula (I): wherein X and X' are -N(COOCR3R2OCOR1)-, -O- or the like, R1 is alkyl substituted with carbamoyl, lower alkylcarbamoyl, carbamoyloxy, lower alkylcarbamoyloxy, acetylamino or the like, R2 and R3 are hydrogen or the like, Y and Y' are lower alkyl, lower alkenyl or the like, ring A, ring B and ring C are optionally substituted aromatic carbocycle or optionally substituted heterocycle, W1, W2 and/or W3 are a bond or the like, and V1 and V2 are a single bond or the like, or a pharmaceutically acceptable salt or a solvate thereof, as well as a pharmaceutical composition containing the present compound.

  提供了一种由式(I)代表的化合物： 其中X和X'为-N(COOCR3R2OCOR1)-、-O-或类似物，R1为被氨基甲酰基、低级烷基氨基甲酰基、氨基甲酰氧基、低级烷基氨基甲酰氧基、乙酰氨基或类似物取代的烷基，R2和R3为氢或类似物，Y和Y'为低级烷基、低级烯基或类似物，环A、环 B 和环 C 是任选取代的芳香族碳环或任选取代的杂环，W1、W2 和/或 W3 是键或类似物，V1 和 V2 是单键或类似物，或其药学上可接受的盐或溶液，以及含有本化合物的药物组合物。
• HBED-Bisphosphonates, Radiometal Conjugates and Their Use as Theranostic Agents
  申请人：Five Eleven Pharma Inc.

  公开号：US20170022224A1

  公开（公告）日：2017-01-26

  The present invention relates to compounds according to Formula I or Formula II, which are potential bone imaging agents. Certain compounds labeled with 68 Ga displayed excellent bone uptake and retention. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof.
• NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY
  申请人：Almirall, S.A.

  公开号：US20200255478A1

  公开（公告）日：2020-08-13

  The invention relates to peptidic compounds, which peptidic compounds are compounds of formula (I)′, or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer thereof: wherein R 1 ; R 2 ; s; t; u; Aa 78 and G 1 are as defined herein. The peptidic compounds are useful in activating the Nrf2 pathway.
• US6765096B1
  申请人：——

  公开号：US6765096B1

  公开（公告）日：2004-07-20
• [EN] NOVEL GLUCAGON ANALOGUES<br/>[FR] NOUVEAUX ANALOGUES DE GLUCAGON
  申请人：NOVO NORDISK AS

  公开号：WO2012130866A1

  公开（公告）日：2012-10-04

  The present invention relates to novel glucagon peptides with improved stability and solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The glucagon peptides of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.